

## Original Research Article

# ACTIVITY OF HYDROETHANOLIC LEAF EXTRACT OF *TECOMA STANS* AGAINST BREAST CANCER CELLS LINE - MCF - 7

**Running Title :-** Antioxidant and Cytotoxic effect of *Tecoma stans* against Breast cancer

## ABSTRACT:

**Background:** Cancer is abnormal growth of cells, which invade or spread to other parts of the body. There are over 200 types of cancers. Breast cancer is a cancer which develops in tissues of the breast, most commonly originating from the inner lining of milk ducts or lobules that supply ducts with milk. *Tecoma stans* commonly known as trumpet flower is a yellow trumpet shaped flower belonging to Bignoniaceae, and is native to Americas. It has anti cancer and anti proliferative properties.

**Aim:** Aim of the is to analyse the anti cancer activity of *Tecoma stans* against breast cancer cells MCF-7.

**Materials and Methods:** Breast cancer cell line (MCF-7) was purchased from National Centre for Cell Sciences (NCCS), Pune, India. Cell viability test was done by MTT assay. Bcl2 and BclxL gene expression analysis was done by Real Time-PCR. The obtained data were analysed statistically by one-way analysis of variance and Duncan's multiple range test with Graph Pad Prism version 5 to analyse the significance. The significance was considered at  $p < 0.05$  level in Duncan's test.

**Results:** The results suggest Bcl2 mRNA gene expression is reduced on induction of 400, 500 ug/ml of *Tecoma stans* with significant difference in comparison with control. Bcl-xL mRNA gene expression is slightly reduced on induction of 400, 500  $\mu\text{g}/\text{mL}$  of *Tecoma stans* with no significant difference in comparison with control.

**Conclusion:** From the obtained results, it can be concluded that hydroethanolic leaf extract of *Tecoma stans* possess anticancer activity against breast cancer cells with respect to Bcl2 mRNA gene expression as compared to Bcl xL mRNA gene expression. If complete research is done, we can use this drug to treat various cancers.

**Key words:** *Tecoma stans*; cancer; gene expression; Bcl2; BclxL; Innovative

**INTRODUCTION :**

Cancer is abnormal growth of cells, which invade or spread to other parts of the body. There are over 200 types of cancers. Possible symptoms are cough, weight loss, abnormal bleeding and change in bowel movements. Tobacco usage is the main cause of about 22% of deaths of cancer. In the year 2015, about 90.5 million had been diagnosed with cancer<sup>1</sup>. As of 2019, about 18 million new cases occur annually as per the statistics <sup>2</sup>. 8.8 million people die annually due to cancer. There are four different types of cancer: carcinomas, sarcomas, leukemias and lymphomas. The most common types of cancer in males are colorectal cancer, lung cancer and stomach cancer. In females, the most common types of cancers are breast cancer, colorectal cancer, lung cancer and cervical cancer. Breast cancer ranked first among the most diagnosed cancers in India.

Breast cancer is a cancer that originates in the tissues of the breast . Breast cancer is diagnosed very commonly in women and rarely in men. In 2004, 5,19,000 people died due to breast cancer worldwide <sup>3</sup>. Cancer cells are formed from the normal cells due to a modification of DNA or RNA. Due to improper functioning of the immune system, cancer develops. Breast cancer develops mostly in cells that line the ducts (ductal cancer). Some of them develop in cells that line the lobules (lobular cancers). The first symptoms of breast cancer is appearance as an area of thickened tissue in the breast or a lump in the breast, or an armpit. Other symptoms include pain in armpits or breast which doesn't change with the monthly cycle, redness of skin of breast, rash around or one of the nipples, blood discharge from a nipple, or change occur in size occur in size or shape of the breast, and peeling, flaking, or scaling of the skin on the breast or nipple. Breast cancer can be treated stage wise. The experience from our previous studies <sup>4 5,6 5789108,101112 13</sup> have led us to focus on the current topic.

*Tecoma stans* is commonly known as trumpet flower is a yellow trumpet shaped flower belonging to Bignoniaceae, and is native to Americas. Yellow, trumpet brush, yellow bells are few common names to the species. The genus *Tecoma* comprises 14 species of small trees. *Tecoma* is an ornamental plant which is fast growing in India <sup>14</sup> It is widely spread in an area of tropical and subtropical regions. It's native to Florida, West Indies and Mexico to South America. A leafed *Tecoma stans* infusion can be taken orally for treating diabetes and stomach pains. Most people are not aware that the species *Tecoma stans* have anticancer properties in their leaf extracts. **Our team has research experience that has translate into good quality researches** <sup>15-</sup>

<sup>22 23 24 25 26,27 28 29 30-34</sup> The aim of the present study is to analyse the activity of hydroethanolic

leaf extract of *Tecoma stans* against breast cancer cells through mRNA gene expression of Bcl2 and Bcl xl genes.

## **MATERIALS AND METHODS:**

This is an in-vitro experimental study conducted in a private dental college and hospitals in Chennai. The study is approved by the institutional review board.

### **Procedure**

Dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical Pvt Ltd, USA. Trypsin-EDTA, fetal bovine serum (FBS), antibiotics-antimycotics, RPMI 1640 medium and phosphate buffered saline (PBS) were purchased from Gibco, Canada. (5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolocarboyanine iodide) and Real Time PCR kit was purchased TAKARA (Meadowvale Blvd, Mississauga, ON L5N 5S2, Canada).

### **Cell lines and cell culture**

Human breast cancer cell line (MCF-7) was purchased from National Centre for Cell Sciences (NCCS), Pune, India. Cells were cultured in DMEM medium (Thermo Fisher Scientific, CA, USA) containing 10% fetal bovine serum (Thermo Fisher Scientific, CA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Thermo Fisher Scientific, CA, USA) at 37°C with 5% CO<sub>2</sub>.

### **Cell proliferation assay by cell viability**

Cell proliferation was determined using the MTT assay. MCF-7 cells were seeded in 96-well plates with  $5 \times 10^3/200 \mu\text{l}$  and cultured overnight. Cell viability was assayed using a modified colorimetric technique that is based on the ability of live cells to convert MTT, a tetrazolium compound into purple formazan crystals by mitochondrial reductases (Mosmann, 1983). Briefly, MCF-7 cells ( $1 \times 10^4/\text{well}$ ) were exposed to different concentrations of hydroethanolic leaf extract of *Tecomastans* (100-500µg) with MCF-7 cells for 48 h. At the end of the treatment, 100

$\mu$ l of 0.5 mg/ml MTT solution was added to each well and incubated at 37 °C for an hour. Then the formazan crystals formed were dissolved in dimethyl sulfoxide (100  $\mu$ l ) and incubated in dark for an hour. Then the intensity of the color developed was assayed using a Micro ELISA plate reader at 570 nm. The number of viable cells was expressed as the percentage of control cells cultured in serum-free medium. Cell viability in the control medium without any treatment was represented as 100%. The cell viability is calculated using the formula: % cell viability = [A570 nm of treated cells/A570 nm of control cells]  $\times$  100.

### **Gene expression analysis by Real Time-PCR: Procedure**

Samples from each group were submerged in 2 ml Trizol (Invitrogen, Carlsbad, CA, USA) for RNA extraction and stored at  $-80^{\circ}$  C until further processed. cDNA synthesis was performed on 2  $\mu$ g RNA in a 10  $\mu$ l sample volume using Superscript II reverse transcriptase (Invitrogen) as recommended by the manufacturer. Real-time PCR array analysis was performed in a total volume of 20  $\mu$ l including 1  $\mu$ l cDNA, 10  $\mu$ l qPCR Master Mix 2x (Takara, USA) and 9  $\mu$ l ddH<sub>2</sub>O. Reactions were run on an CFX96 Touch Real-Time PCR Detection System (Bio-Rad, USA) using universal thermal cycling parameters (95° C for 5 min, 40 cycles of 15 sec at 95° C, 15 sec at 60° C and 20 sec at 72° C; followed by a melting curve: 5 sec at 95° C, 60 sec at 60° C and continued melting). For quality control purposes, melting curves were acquired for all samples. The specificity of the amplification product was determined by melting curve analysis for each primer pairs. The data were analyzed by comparative CT method and the fold change is calculated by  $2^{-\Delta\Delta CT}$  method described by Schmittgen and Livak (2008) using CFX Manager Version 2.1 (Bio Rad, USA).

### **Statistical analysis**

The obtained gene expression status of control and test groups of different dosages were analyzed statistically by one-way analysis of variance (ANOVA) and Duncan's multiple range test with a computer-based software (Graph Pad Prism version 5) to analyze the significance of individual variations among the control and experimental groups. The significance was considered at  $p < 0.05$  level in Duncan's test.

## RESULTS:

### Effect of *Tecoma stans* on the Cell Viability:

Cell viability of Human breast cancer cells (MCF-7 cells) was determined using MTT assay after administering the different doses of *Tecoma stans*. It was found to exhibit inhibition of breast cancer cells by decreasing the percentage of viability of cancer cells in a dose dependent manner when compared to control. It was found that maximum inhibition of cell growth was at concentration (100-400 $\mu$ g/ml) used in this study when compared to control. (Figure 1)

### Effect of Bcl-2 mRNA expression on the MCF-7 cancer cells (Fold change over control)

The mRNA expression of Bcl-2 was assessed in a dose dependent manner. The cancer cells were significantly inhibited and it was found that there was significant reduction in mRNA expression of Bcl-2 when compared to control at a dose of 400  $\mu$ g/ml. Further there was significant reduction in mRNA expression of Bcl-2 when compared to control at a dose of 500 $\mu$ g/ml. Thus the decrease in gene expression was in dose dependent manner.

### Effect of Bcl-xl mRNA expression on MCF-7 cells (Fold change over control)

The mRNA expression of Bcl-xl was assessed in a dose dependent manner. The cancer cells were significantly inhibited and it was found that there was significant reduction in mRNA expression of Bcl-xl when compared to control at a dose of 400 $\mu$ g/ml. Further there was significant reduction in mRNA expression of Bcl-xl when compared to control at a dose of 500 $\mu$ g/ml. Thus interestingly, the decrease was in dose dependent manner.

**Table 1:** Percentage of Cell Viability

Concentration	Cell viability in %
0	100
100	90
200	80
300	65
400	50
500	48
500	45




Figure 1: Effect of hydroethanolic leaf extract of *Tecoma stans* on cell viability in MCF-7 cells. X axis represents different concentrations of *Tecoma stans* and the y axis represents the percentage of cell viability. There is a statistically significant difference observed in comparison with control in dose dependent manner with  $p < 0.05$ , a-compared with untreated control cells, b-compared with 100µg treated cells, c-compared with 200µg treated cells.




Figure 2: Effect of hydroethanolic leaf extract of *Tecoma stans* on Bcl-2 mRNA expression in MCF-7 cells. X axis represents different concentrations of *Tecoma stans* and Y axis represents the fold change over control. a-compared with untreated control cells with 400 $\mu$ g/ml and 500 $\mu$ g/ml treated MCF-7 cells. There is a statistically significant difference between the test and control groups with p value < 0.05.

**Bcl-xl mRNA expression (Fold change over control)**




Figure 3: Effect of hydroethanolic leaf extract of *Tecoma stans* on Bcl-xL mRNA expression in MCF-7 cells. X axis represents different concentrations of *Tecoma stans* and Y axis represents the fold change over control. a-compared with untreated control cells with 400 $\mu$ g/ml, b-compared with 500 $\mu$ g/ml treated MCF-7 cells. There is no significant difference between the test and control groups with p value < 0.05.

## DISCUSSION:

*Tecoma stans* is a species on which different extracts of the plant are used for treating many diseases. This flower is taken to analyse the anti cancer activity against breast cancer cells. Two gene variables namely Bcl2 and BclxL are taken. Bcl2 gene on induction of increase in dosage from 400 $\mu$ g/ml to 500 $\mu$ g/ml there was an increase in the anticancer activity in comparison with control. BclxL gene induction of increase in dosage from 400 $\mu$ g/ml to 500 $\mu$ g/ml there was no significant increase in the anticancer activity in comparison with control.

The aqueous extract of flowers has anti-proliferative and antioxidant properties <sup>35</sup>. The methanolic extract of leaves has antispasmodic property <sup>36</sup>. Aqueous extracts of leaves possess antidiabetic activity by streptozotocin induced diabetes in Sprague dawley rats method <sup>37</sup>. The ethanol, methanol and aqueous extracts of leaves possess anti microbial activity and antioxidant activity <sup>38</sup>. The ethanol, methanol and aqueous extracts of heart wood of stem

possess anti microbial activity against human pathogenic microbes <sup>39</sup> <sup>40</sup>. The alcoholic leaf extract of flowers possess antifungal activity <sup>41</sup> <sup>42</sup>.

Cancer is one of the ailments which cannot be completely cured by chemotherapy. Research on *Tecoma stans* is very limited to generalise the activity in breast cancer cells. Although there are many new innovative approaches for discovery of drugs, such as combinatorial chemistry and computer based molecular modelling design, not even one of them cannot replace the importance of natural ailments. <sup>43</sup> <sup>44</sup>.

Bcl2 mRNA gene expression is reduced on induction of 400, 500 µg/ml of *Tecoma stans* of significant difference in comparison with control. The article in Bcl2 in breast cancer is a favourable prognostic marker of molecular subtypes and independent adjuvant therapy is received <sup>45</sup>. Instead of Mcl-1 alone, or in the combination with other anti-apoptotic Bcl2 family members, may be an essential driver of tumor progression and mediator of therapeutic existence in breast cancer. *Tecoma stans* in Bcl2 gene have anticancer properties against breast cancer cells and can be treated or cured with natural ailments.

Bcl xL mRNA gene expression is slightly reduced on induction of 400, 500 µg/ml of *Tecoma stans* with no significant difference in comparison with control. The article is targeting Bcl-xL improves the efficacy of bromodomain and extra terminal protein inhibitors in triple negative breast cancer by eliciting the death of senescent cells <sup>46</sup>. Bcl xL gene should be predictive in tumour responses. There are no previous articles of anticancer properties of *Tecoma stans*. *Tecoma stans* in Bcl-xL have anticancer properties against breast cancer cells and can be cured without synthetic drugs and side effects.

The sample size used for the study is very less and cannot be generalised for a research to be done. It needs a large scale study. Large-scale study should done on *Tecoma stans* for anticancer activity against breast cancer in in-vivo animal studies and clinical trials.

## **CONCLUSION:**

From the obtained results, it can be concluded that hydroethanolic leaf extract of *Tecoma stans* possess anticancer activity against breast cancer cells with respect to Bcl2 mRNA gene

expression as compared to Bcl xL mRNA gene expression. To generalize the result the study should be conducted with large sample size and invivo studies.

● **COMPETING INTERESTS DISCLAIMER:**

● Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

●

●

**REFERENCES:**

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1545–602.
2. Sciacovelli M, Schmidt C, Maher ER, Frezza C. Metabolic Drivers in Hereditary Cancer Syndromes [Internet]. Vol. 4, *Annual Review of Cancer Biology*. 2020. p. 77–97. Available from: <http://dx.doi.org/10.1146/annurev-cancerbio-030419-033612>
3. Grimsey E. An Overview of the Breast and Breast Cancer [Internet]. *Breast Cancer Nursing Care and Management*. 2013. p. 1–18. Available from: <http://dx.doi.org/10.1002/9781118784921.ch1>
4. Shruthi M, Preetha S. Effect of Simple Tongue Exercises in Habitual Snorers [Internet]. Vol. 11, *Research Journal of Pharmacy and Technology*. 2018. p. 3614. Available from: <http://dx.doi.org/10.5958/0974-360x.2018.00665.0>
5. Preetha S, Packyanathan J. Comparison of the effect of Yoga, Zumba and Aerobics in controlling blood pressure in the Indian population [Internet]. Vol. 9, *Journal of Family Medicine and Primary Care*. 2020. p. 547. Available from: [http://dx.doi.org/10.4103/jfmpc.jfmpc\\_607\\_19](http://dx.doi.org/10.4103/jfmpc.jfmpc_607_19)
6. J SK, Saveetha Dental College and Hospitals, Road PH, Chennai, Tamilnadu, Preetha S, et al. Effect of aerobics exercise and yoga on blood pressure in hypertensives [Internet]. Vol. 6, *International Journal of Current Advanced Research*. 2017. p. 3124–6. Available from: <http://dx.doi.org/10.24327/ijcar.2017.3126.0200>
7. Prathap L, Suganthirababu P, Ganesan D. Fluctuating Asymmetry of Dermatoglyphics and DNA Polymorphism in Breast Cancer Population [Internet]. Vol. 10, *Indian Journal of Public Health Research & Development*. 2019. p. 3574. Available from: <http://dx.doi.org/10.5958/0976-5506.2019.04141.x>

8. Lavanya J, Prathap S, Alagesan J. Digital and palmar dermal ridge patterns in population with breast carcinoma. *Biomedicine*. 2014 Jul 1;34(3):315–21.
9. Prathap L, Jagadeesan V. Association of quantitative and qualitative dermatoglyphic variable and DNA polymorphism in female breast cancer population. *Online J Health [Internet]*. 2017; Available from: [https://www.researchgate.net/profile/Prathap\\_Suganthirababu/publication/321606278\\_Association\\_of\\_Quantitative\\_and\\_Qualitative\\_Dermatoglyphic\\_Variable\\_and\\_DNA\\_Polymorphism\\_in\\_Female\\_Breast\\_Cancer\\_Population/links/5a28c8f1a6fdcc8e8671c0cd/Association-of-Quantitative-and-Qualitative-Dermatoglyphic-Variable-and-DNA-Polymorphism-in-Female-Breast-Cancer-Population.pdf](https://www.researchgate.net/profile/Prathap_Suganthirababu/publication/321606278_Association_of_Quantitative_and_Qualitative_Dermatoglyphic_Variable_and_DNA_Polymorphism_in_Female_Breast_Cancer_Population/links/5a28c8f1a6fdcc8e8671c0cd/Association-of-Quantitative-and-Qualitative-Dermatoglyphic-Variable-and-DNA-Polymorphism-in-Female-Breast-Cancer-Population.pdf)
10. Lavanya J, Kumar VJ, Sudhakar N, Prathap S. Analysis of DNA repair genetic polymorphism in breast cancer population. *Int J Pharma Bio Sci [Internet]*. 2015; Available from: [https://scholar.google.ca/scholar?cluster=8949053652564257518&hl=en&as\\_sdt=0,5&scio dt=0,5](https://scholar.google.ca/scholar?cluster=8949053652564257518&hl=en&as_sdt=0,5&scio dt=0,5)
11. Prathap L, Suganthirababu P. Estrogen Exposure and its Influence in DNA Repair Genetic Variants in Breast Cancer Population [Internet]. Vol. 13, *Biomedical and Pharmacology Journal*. 2020. p. 1321–7. Available from: <http://dx.doi.org/10.13005/bpj/2001>
12. Ravikumar H, Prathap L, Preetha S. ANALYSIS OF PALMAR ATD ANGLE IN POPULATION WITH MALOCCLUSION. 2020 Jan 1;1174–82.
13. Prathap L. INTERPLAY OF OXIDATIVE STRESS AND LIPOPROTEINS IN BREAST CARCINOMA INITIATION, PROMOTION AND PROGRESSION -A SYSTEMATIC REVIEW. *PalArch's Journal of Archaeology of Egypt/ Egyptology [Internet]*. 2021 Jan 7 [cited 2021 Mar 9];17(7). Available from: <http://dx.doi.org/>
14. Anand M, Basavaraju R. A review on phytochemistry and pharmacological uses of *Tecoma stans* (L.) Juss. ex Kunth. *J Ethnopharmacol*. 2021 Jan 30;265:113270.
15. Sekar D, Lakshmanan G, Mani P, Biruntha M. Methylation-dependent circulating microRNA 510 in preeclampsia patients. *Hypertens Res*. 2019 Oct;42(10):1647–8.
16. Princeton B, Santhakumar P, Prathap L. Awareness on Preventive Measures taken by Health Care Professionals Attending COVID-19 Patients among Dental Students. *Eur J Dent*. 2020 Dec;14(S 01):S105–9.
17. Logeshwari R, Rama Parvathy L. Generating logistic chaotic sequence using geometric pattern to decompose and recombine the pixel values. *Multimed Tools Appl*. 2020 Aug;79(31-32):22375–88.
18. Johnson J, Lakshmanan G, M B, R M V, Kalimuthu K, Sekar D. Computational identification of MiRNA-7110 from pulmonary arterial hypertension (PAH) ESTs: a new microRNA that links diabetes and PAH. *Hypertens Res*. 2020 Apr;43(4):360–2.
19. Paramasivam A, Priyadharsini JV, Raghunandhakumar S, Elumalai P. A novel COVID-19 and its effects on cardiovascular disease. *Hypertens Res*. 2020 Jul;43(7):729–30.
20. Pujari GRS, Subramanian V, Rao SR. Effects of *Celastrus paniculatus* Willd. and *Sida*

cordifolia Linn. in Kainic Acid Induced Hippocampus Damage in Rats. *Ind J Pharm Educ.* 2019 Jul 3;53(3):537–44.

21. Rajkumar KV, Lakshmanan G, Sekar D. Identification of miR-802-5p and its involvement in type 2 diabetes mellitus. *World J Diabetes.* 2020 Dec 15;11(12):567–71.
22. Ravisankar R, Jayaprakash P, Eswaran P, Mohanraj K, Vinitha G, Pichumani M. Synthesis, growth, optical and third-order nonlinear optical properties of glycine sodium nitrate single crystal for photonic device applications. *J Mater Sci: Mater Electron.* 2020 Oct;31(20):17320–31.
23. Wu S, Rajeshkumar S, Madasamy M, Mahendran V. Green synthesis of copper nanoparticles using *Cissus vitiginea* and its antioxidant and antibacterial activity against urinary tract infection pathogens. *Artif Cells Nanomed Biotechnol.* 2020 Dec;48(1):1153–8.
24. Vikneshan M, Saravanakumar R, Mangaiyarkarasi R, Rajeshkumar S, Samuel SR, Suganya M, et al. Algal biomass as a source for novel oral nano-antimicrobial agent. *Saudi J Biol Sci.* 2020 Dec;27(12):3753–8.
25. Alharbi KS, Fuloria NK, Fuloria S, Rahman SB, Al-Malki WH, Javed Shaikh MA, et al. Nuclear factor-kappa B and its role in inflammatory lung disease. *Chem Biol Interact.* 2021 Aug 25;345:109568.
26. Rao SK, Kalai Priya A, Manjunath Kamath S, Karthick P, Renganathan B, Anuraj S, et al. Unequivocal evidence of enhanced room temperature sensing properties of clad modified Nd doped mullite Bi<sub>2</sub>Fe<sub>4</sub>O<sub>9</sub> in fiber optic gas sensor [Internet]. Vol. 838, *Journal of Alloys and Compounds.* 2020. p. 155603. Available from: <http://dx.doi.org/10.1016/j.jallcom.2020.155603>
27. Bhavikatti SK, Karobari MI, Zainuddin SLA, Marya A, Nadaf SJ, Sawant VJ, et al. Investigating the Antioxidant and Cytocompatibility of *Mimusops elengi* Linn Extract over Human Gingival Fibroblast Cells. *Int J Environ Res Public Health* [Internet]. 2021 Jul 4;18(13). Available from: <http://dx.doi.org/10.3390/ijerph18137162>
28. Marya A, Karobari MI, Selvaraj S, Adil AH, Assiry AA, Rabaan AA, et al. Risk Perception of SARS-CoV-2 Infection and Implementation of Various Protective Measures by Dentists Across Various Countries. *Int J Environ Res Public Health* [Internet]. 2021 May 29;18(11). Available from: <http://dx.doi.org/10.3390/ijerph18115848>
29. Barma MD, Muthupandiyani I, Samuel SR, Amaechi BT. Inhibition of *Streptococcus mutans*, antioxidant property and cytotoxicity of novel nano-zinc oxide varnish. *Arch Oral Biol.* 2021 Jun;126:105132.
30. Vijayashree Priyadharsini J. In silico validation of the non-antibiotic drugs acetaminophen and ibuprofen as antibacterial agents against red complex pathogens. *J Periodontol.* 2019 Dec;90(12):1441–8.
31. Priyadharsini JV, Vijayashree Priyadharsini J, Smiline Girija AS, Paramasivam A. In silico analysis of virulence genes in an emerging dental pathogen *A. baumannii* and related species [Internet]. Vol. 94, *Archives of Oral Biology.* 2018. p. 93–8. Available from: <http://dx.doi.org/10.1016/j.archoralbio.2018.07.001>

32. Uma Maheswari TN, Nivedhitha MS, Ramani P. Expression profile of salivary micro RNA-21 and 31 in oral potentially malignant disorders. *Braz Oral Res.* 2020 Feb 10;34:e002.
33. Gudipani RK, Alam MK, Patil SR, Karobari MI. Measurement of the Maximum Occlusal Bite Force and its Relation to the Caries Spectrum of First Permanent Molars in Early Permanent Dentition. *J Clin Pediatr Dent.* 2020 Dec 1;44(6):423–8.
34. Chaturvedula BB, Muthukrishnan A, Bhuvanaraghan A, Sandler J, Thiruvengkatachari B. Dens invaginatus: a review and orthodontic implications. *Br Dent J.* 2021 Mar;230(6):345–50.
35. Ghar MK, Yahyavi H. Antispasmodic Effect of Piper nigrum Fruit Hot Water Extract on Rat Ileum [Internet]. Vol. 11, *Pakistan Journal of Biological Sciences.* 2008. p. 1492–6. Available from: <http://dx.doi.org/10.3923/pjbs.2008.1492.1496>
36. Marzouk M, Gamal-Eldeen A, Mohamed M, El-Sayed M. Anti-proliferative and antioxidant constituents from *Tecoma stans*. *Z Naturforsch C.* 2006 Nov;61(11-12):783–91.
37. Aguilar-Santamaría L, Ramírez G, Nicasio P, Alegría-Reyes C, Herrera-Arellano A. Antidiabetic activities of *Tecoma stans* (L.) Juss. ex Kunth. *J Ethnopharmacol.* 2009 Jul 15;124(2):284–8.
38. Larbie C, Nyarkoh CO, Adjei CO. Phytochemical and Safety Evaluation of Hydroethanolic Leaf Extract of *Tecoma stans* (L.) Juss. ex Kunth [Internet]. Vol. 2019, *Evidence-Based Complementary and Alternative Medicine.* 2019. p. 1–12. Available from: <http://dx.doi.org/10.1155/2019/7417624>
39. Bhat MA. Remedial and Phytochemical Review Study on *Tecoma Stans* [Internet]. Vol. 6, *International Journal of Agriculture & Environmental Science.* 2019. p. 40–6. Available from: <http://dx.doi.org/10.14445/23942568/ijaes-v6i2p108>
40. Robles-Zepeda RE, Velázquez-Contreras CA, Garibay-Escobar A, Gálvez-Ruiz JC, Ruiz-Bustos E. Antimicrobial activity of Northwestern Mexican plants against *Helicobacter pylori*. *J Med Food.* 2011 Oct;14(10):1280–3.
41. Gupta V, Dhakad U. *Pharmacological Activity of Tecoma Stans Flower: Analgesic, Antipyretic, Antidiabetic and Antifungal Activity.* LAP Lambert Academic Publishing; 2014. 80 p.
42. Meelah MM, Mdee LK, Eloff JN. *Tecoma stans* (Bignoniaceae), leaf extracts, fractions and isolated compound have promising activity against fungal phytopathogens [Internet]. Vol. 36, *Suid-Afrikaanse Tydskrif vir Natuurwetenskap en Tegnologie.* 2017. Available from: <http://dx.doi.org/10.4102/satnt.v36i1.1489>
43. Jagetia GC, Rao SK. Evaluation of the Antineoplastic Activity of Guduchi (*Tinospora cordifolia*) in Ehrlich Ascites Carcinoma Bearing Mice [Internet]. Vol. 29, *Biological and Pharmaceutical Bulletin.* 2006. p. 460–6. Available from: <http://dx.doi.org/10.1248/bpb.29.460>
44. Heinrich M, Bremner P. Ethnobotany and Ethnopharmacy - Their Role for Anti-Cancer Drug Development [Internet]. Vol. 7, *Current Drug Targets.* 2006. p. 239–45. Available from: <http://dx.doi.org/10.2174/138945006776054988>

45. Dawson S-J, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br J Cancer*. 2010 Aug 24;103(5):668–75.
46. Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, et al. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. *J Biol Chem*. 2019 Jan 18;294(3):875–86.

UNDER PEER REVIEW